Jade Biosciences (JBIO) Share-based Compensation (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Share-based Compensation data on file, last reported at $7.4 million in Q1 2026.

• Quarterly Share-based Compensation rose 205.61% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.0 million (up 230.09% YoY) and the FY2025 annual result came in at $20.0 million, up 76.9% from the prior year.
• Share-based Compensation retreated to $7.4 million in Q1 2026, from $9.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $9.4 million in Q4 2025 to a low of $27000.0 in Q3 2024.
• A 5-year average of $3.4 million and a median of $3.2 million in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation slumped 99.17% — and 2025, when it jumped 15807.41%.
• Tracing JBIO's Share-based Compensation over 5 years: stood at $4.7 million in 2022, then tumbled by 30.99% to $3.3 million in 2023, then plunged by 61.37% to $1.3 million in 2024, then jumped by 648.09% to $9.4 million in 2025, then dropped by 21.19% to $7.4 million in 2026.
• The last three Share-based Compensation figures came in at $7.4 million (Q1 2026), $9.4 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.